Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer is a research paper published in Journal for ImmunoTherapy of Cancer (2025). On theSindex it has a DataRank of 0.416. It has been cited 15 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.416
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →NIH
Grant: R01AI158488
NIH
Grant: R01AI169188
Rob and Karen Hale Distinguished Chair in Surgical Oncology
Grant: n/a
National Institutes of Health
Grant: 5R01AI158488-02
CDK4/6 inhibition during CD8 T cell priming potentiates memory formation in mice and humans
National Institutes of Health
Grant: 5R01AI169188-03
Molecular Pathways Regulating Tissue-resident Memory T cells in the Gut
Fields of Study
MeSH Terms
Keywords